Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging Markets, U.S. Provide Better Incubation Environment For Biotech Than Europe, Says Sanofi’s Viehbacher

This article was originally published in PharmAsia News

Executive Summary

Taking the helm of EFPIA, Viehbacher says R&D and innovation are the keys to rescuing Europe from its economic slump, but more harmonization across the pharmaceutical sector will be needed too.

You may also be interested in...



Germany’s IQWiG Pans Sanofi’s Lyxumia For Wrong Comparator Choices

Sanofi’s failure to align its comparator selection with that of Germany’s reimbursement authorities has resulted in dismissal of Lyxumia for diabetes type 2, although the company will have an opportunity to challenge the decision.

EU’s IMI, Drug Makers And Universities Join In New R&D Effort

Europe’s latest push to speed up new medicine discovery will see a new European Lead Factory set up under the EU’s Innovative Medicines Initiative, combining a library of up to 500,000 drug candidates from industry and academia and high-throughput screening centers to identify and generate new therapies.

GSK To Downplay Europe Because of Poor Innovation Support, Focuses On U.S. and Japan Instead

GSK CEO Andrew Witty is scathing about the lack of support in Europe for innovation, and the company will now prioritize the U.S., Japan and emerging markets for the development of new products

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC084930

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel